Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224629 | 0.84 | LRRK2 (0.71) | LRRK2 | |
| SCHEMBL883177 | 0.79 | LRRK2 (0.63) | LRRK2UTS2R | |
| SCHEMBL878306 | 0.78 | LRRK2 (0.76) | LRRK2UTS2R | |
| SCHEMBL10224631 | 0.76 | LRRK2 (0.69) | LRRK2 | |
| SCHEMBL15267024 | 0.76 | LRRK2 (1.00) | LRRK2UTS2R | |
| SCHEMBL15266515 | 0.75 | LRRK2 (0.74) | LRRK2 | |
| SCHEMBL15266400 | 0.75 | LRRK2 (0.74) | LRRK2 | |
| SCHEMBL416713 | 0.75 | LRRK2 (0.66) | LRRK2UTS2R | |
| SCHEMBL19730075 | 0.75 | LRRK2 (0.66) | LRRK2UTS2R | |
| SCHEMBL15280022 | 0.74 | LRRK2 (0.70) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | GENENTECH, INC. (US) | 2014-09-25 | — | — | US | claimed |
| WO-2013139882-A1 | PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | GENENTECH, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| WO-2013139882-A1 | PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013139882-A1 | PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288043-A1 | PYRAZOLOPYRIDINE COMPOUNDS | KCNJ11, P2RX4, P2RY4 | LRRK2 3488/4885UTS2R 1420/4885 |
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | LRRK2 1512/4885UTS2R 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.